Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 638.00p 634.00p 638.00p 640.00p 634.00p 640.00p 42,788 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 244

International Biotechnol... Share Discussion Threads

Showing 201 to 220 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
17/10/2011
15:45
Date NAV Pence Friday 14(th) October Excluding Income 174.08
davebowler
19/9/2011
09:55
Thursday 15 September NAV Excluding Income 172.77
davebowler
09/9/2011
12:26
NAV Thursday 08 September 170.52
davebowler
05/9/2011
13:56
NAV Friday 02 September Excluding Income 164.25
davebowler
21/6/2011
09:51
http://www.investmentweek.co.uk/investment-week/analysis/2075951/medical-innovation-brings-health-biotech-sector
davebowler
19/5/2011
13:23
18 May 2011 International Biotechnology Trust plc The Board of International Biotechnology Trust plc announces that the unaudited net asset value per share Date NAV Pence Tuesday 17 May Excluding Income 183.34
davebowler
19/5/2011
13:23
http://www.moneyweek.com/news-and-charts/people-in-the-news/guru-watch/drug-stocks-pharmaceuticals-neil-woodford-10713
davebowler
26/4/2011
13:58
Wednesday 20 April NAV 179.01
davebowler
14/4/2011
10:10
Tuesday 12 April NAV 177.3
davebowler
11/4/2011
13:51
Friday 08 April NAV Excluding Income 176.90
davebowler
31/12/2010
16:21
Thursday 30 December NAV Excluding Income 181.09
davebowler
27/12/2010
10:42
https://www.winsresearch.co.uk/secure/files.php?file_id=334&file_type=wins-update
davebowler
24/12/2010
11:25
23/12 NAV 180.35
davebowler
21/12/2010
09:33
now at 18% discount to NAV; http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=ITIBT&univ=T
davebowler
20/12/2010
15:47
Intl. Biotechnology Trust PLC 17 December 2010 INTERNATIONAL BIOTECHNOLOGY TRUST PLC Portfolio Update as at 30 November 2010 Total net assets GBP99.4m NAV per share 166.3p Share price 137.0p Total value of unquoted investments GBP23.3m Total number of portfolio companies 60 Cash 1% NAV Cash committed and reserved to 9% NAV unquoted investments Portfolio companies with < 1 year 10% NAV of cash Top Ten Holdings Company Name % NAV Celgene 5.80 Micromet 5.77 Amgen 5.30 Shire Ltd 5.16 Gilead Sciences 4.83 Alexion Pharmaceuticals 3.54 Teva 3.43 Insulet 3.39 Genzyme 3.27 Cadent 3.25 ----------- Total 43.74 Geographical Allocation % United States 74 Europe 23 Australia 2 Cash 1 ----------- Total 100 Quoted/Unquoted allocation % Quoted 76 Unquoted 23 Cash 1 ----------- Total 100
davebowler
03/11/2010
09:29
Edison note; During the 12 months to 31 August 2010 International Biotechnology Trust (IBT) underperformed the NASDAQ Biotechnology Index (NASBIOT) – large cap biased by 4.2% in terms of NAV total return, but outperformed Russell 2000 Biotechnology Growth Index (R2BIOG) – small cap biased by 11.5%. In terms of share price total return, IBT outperformed the NASBIOT by 4.2% and the R2BIOG by 19.9%. The superior share price performance, over the NAV, reflects a narrowing of the discount during the period. The manager considers that biotech has suffered from substantial negative sentiment during the last year and investors' appetite for risk is much diminished. The manager expects that, as this returns, valuations will move up from their current historic lows offering significant upside potential. International Biotechnology Trust aims to achieve long-term capital growth by investing in development stage biotechnology companies that are either quoted or unquoted with the potential for high growth.
davebowler
03/11/2010
08:32
New note - http://www.stockopedia.co.uk/research/international-biotech-lonibt-recovery-potential-50097/
yespmedc
21/7/2010
16:37
The Manager of BIOG's views; biotech will be a net beneficiary of healthcare reform; the regulatory environment will continue to improve; M&A activity will continue at a steady pace; and, in P/E terms, biotech valuations are at 15-year lows. As such, the outlook for the sector is positive.
davebowler
08/6/2010
13:55
THE BIOTECH GROWTH TRUST PLC is on a 4% discount to assets yet this is at a 18% discount -crazy!
davebowler
08/6/2010
13:17
http://www.fundstrategy.co.uk/features/trends/new-era-promises-a-sweeter-pill/1012893.article
davebowler
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190724 02:39:25